Parkinson's disease Flashcards

1
Q

Which dopaminergic pathway in the brain degenerates in Parkinson’s disease?

A

Nigrostriatal pathway - cell bodies originate in substantia nigra zona compacta (SNC) and project to striatum (putamen and caudate nucleus) - involved in movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does loss of dopamine trigger motor clinical symptoms?

A

Nigrostriatal pathway that is degenerated is involved in movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which other neuronal pathways are affected in Parkinson’s disease? What are they involved in?

A
  1. Mesolimbic pathway - ventral tegmental area (VTA) –> nucleus accumbens, frontal cortex, limbic cortex, olfactory tubercule - emotion
  2. Tuberoinfundibular system - arcuate nucleus of hypothalamus –> median eminence + pituitary gland - hormone secretion
  3. Mesocortical pathway - VTA to cerebrum - executive functions + behaviour patterns
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the underlying pathological process of PD?

A
  • Severe loss of dopaminergic projection cells in substantia nigra leads to a marked reduction in caudate nucleus/putamen dopamine content
  • Lewy bodies (in neuronal cell bodies) + neurites (in axons) - consist of abnormally phosphorylated neurofilaments (ubiquitin, a-synuclein)
  • Genetics (5% cases) - SRRK2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the principle clinical features of PD?

A

Motor:

  • Postural instability
  • Rigidity
  • Bradykinesia
  • Resting tremor

Non-motor:

  • Orthostatic hypotension
  • Olfactory deficits
  • Neuropsychiatric: sleep disorders, instability, memory loss, depression
  • Autonomic NS: constipation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which drugs are used to treat PD?

A
  1. Levodopa - dopamine replacement
  2. Dopamine receptor agonists
  3. DOPA-D inhibitors
  4. MAO-B inhibitors
  5. COMT inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why are anti-Parkinsonian drugs used in conjunction with one another?

A
  • MAO-B inhibitors reduce the dosage of levodopa required + can increase time before levodopa treatment is needed
  • The effectiveness of L-dopa declines with chronic use
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Parkinson’s disease?

A

Progressive neurodegenerative disorder of movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does levodopa alleviate the symptoms of PD?

A
  • Levodopa rapidly crosses BBB

- Converted to dopamine by DOPA-D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How do dopamine receptor agonists alleviate the symptoms of PD?

A
  • Ergot derivatives or non-ergot derivatives

- Potent agonists of D2Rs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How do MAO-B inhibitors alleviate the symptoms of PD?

A

Selegiline:

  • Prevent breakdown of dopamine within brain
  • Can be given on its own in early stages of disease
  • Or in combination w/L-DOPA –> reduces dose of L-DOPA required –> reduce side effects

Rasagiline (new):

  • Neuroprotective effects in-vivo by inhibiting apoptosis
  • May also slow disease down?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do COMT inhibitors alleviate the symptoms of PD?

A

E.g. tolcapone, entacapone

  • Prevent breakdown of dopamine within brain
  • Prevents breakdown of L-DOPA –> 3-OMD in periphery
  • Tf 3-OMD can’t compete w/L-DOPA for same transport mechanism to cross BBB –> can’t gain access to brain
  • Increases amount of L-DOPA in brain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the side effects of levodopa?

A

Acute:

  • Nausea and vomiting (also converted to dopamine in periphery)
  • Hypotension
  • Psychological effects – schizophrenia like syndrome w/delusions and hallucinations
  • Confusion, disorientation
  • Insomnia, nightmares

Chronic:

  • Dyskinesias – abnormal movements which affect face+limbs; start within 2y; disappear if dose reduced but clinical symptoms reappear
  • “On-Off” Effects – rapid fluctuations in clinical state, where hypokinesia and rigidity may suddenly worsen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the side effects of dopamine receptor agonists?

A

Ergot derivatives:

  • Cardiac fibrosis
  • Valvular disease

Non-ergot derivatives do not have these effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why are COMT inhibitors given with L-DOPA?

A

Increase amount of L-DOPA in brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is nausea caused by L-DOPA treatment be prevented?

A
  • Peripherally acting dopamine antagonist (domperidone)

- DOPA-D inhibitor - can’t cross BBB, prevents peripheral breakdown (carbidopa)

17
Q

Why does L-DOPA become less effective the longer it’s taken?

A
  • L-DOPA requires intact neurones to convert the L-DOPA to dopamine
  • As the disease progresses there are fewer and fewer neurones to convert the drug
18
Q

Why is a DOPA-D inhibitor always given with L-DOPA?

A

E.g. carbidopa

  • Does not cross BBB
  • Prevents peripheral breakdown of L-DOPA
  • Reduces required dose of L-DOPA
  • Reduces nausea and vomiting associated w/peripheral breakdown
19
Q

How is dopamine metabolised?

A

Removed from cleft by dopamine transporter (DAT) and NA transporter (NET)

Broken down by:
MOA-A: DA, NA, 5-HT
MOA-B: DA
COMT: wide distribution, all catecholamines

20
Q

How is dopamine synthesised?

A

L-tyrosine –> L-dopa (by tyrosine hydroxylase - rate-limiting)
L-dopa –> dopamine (by DOPA-D)